All In Biotech

Drug Trial Radar · NCT04470427

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older

Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 30,415 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

30,415

Actual

Start

Jul 27, 2020

Primary completion

Dec 29, 2022

Study completion Dec 29, 2022

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority; National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Jul 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.

Conditions

  • SARS-CoV-2

Interventions

  • mRNA-1273Biological

    Sterile liquid for injection

  • PlaceboBiological

    0.9% sodium chloride (normal saline) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second DoseTime frame: From Day 43 (14 days after second dose) up to approximately 7 months after the second dose
  2. Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First DoseTime frame: up to Day 7 (7 days after first dose)
  3. Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After Second DoseTime frame: Day 29 to Day 35 (from second dose to 7 days after second dose)
  4. Parts A and B: Number of Participants With Medically Attended AEs (MAAEs) and AEs Leading to DiscontinuationTime frame: Day 1 (after dosing) through end of study (up to Day 759)
  5. Parts A and B: Number of Participants With Serious AEs (SAEs)Time frame: Day 1 (after dosing) through end of study (up to Day 759)

Locations

100 sites in 1 country. Site status is shown where the registry gives one.

  • Ascension St. Vincent Birmingham

    Birmingham, Alabama

  • Synexus Clinical Research US, Inc. - Birmingham

    Birmingham, Alabama

  • Hope Research Institute

    Chandler, Arizona

  • Synexus Clinical Research US, Inc. - Phoenix West

    Glendale, Arizona

  • Hope Research Institute

    Peoria, Arizona

  • Hope Research Institute

    Phoenix, Arizona

  • Quality of Life Medical and Research Center

    Tucson, Arizona

  • Baptist Health Center for Clinical Research

    Little Rock, Arkansas

  • Advanced Clinical Research - Rancho Paseo

    Banning, California

  • University of California San Diego

    La Jolla, California

  • eStudySite - La Mesa

    La Mesa, California

  • UCLA Vine Street Clinic CRS

    Los Angeles, California

  • VA Greater Los Angeles Healthcare (veterans only)

    Los Angeles, California

  • Paradigm Clinical Research Institute Inc

    Redding, California

  • Benchmark Research - Sacramento

    Sacramento, California

  • Medical Center For Clinical Research - M3 Wake Research

    San Diego, California

  • University of Colorado Hospital

    Aurora, Colorado

  • Lynn Institute of The Rockies

    Colorado Springs, Colorado

  • George Washington University

    Washington D.C., District of Columbia

  • Accel Research Site

    DeLand, Florida

  • Research Centers of America

    Hollywood, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Synexus - Optimal Research - Melbourne

    Melbourne, Florida

  • Suncoast Research Group

    Miami, Florida

  • University of Miami

    Miami, Florida

  • Synexus Clinical Research US, Inc. - Orlando

    Orlando, Florida

  • Palm Beach Research Center

    West Palm Beach, Florida

  • Grady Health System

    Atlanta, Georgia

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Hope Clinic of The Emory Vaccine Center

    Decatur, Georgia

  • Meridian Clinical Research

    Savannah, Georgia

  • Clinical Research Atlanta

    Stockbridge, Georgia

  • Synexus Clinical Research US, Inc. - Chicago

    Chicago, Illinois

  • UIC Project WISH CRS

    Chicago, Illinois

  • University of Chicago-Hospital

    Chicago, Illinois

  • Johnson County Clin-Trials

    Lenexa, Kansas

  • Alliance for Multispecialty Research

    Newton, Kansas

  • Alliance for Multispecialty Research- East Wichita

    Wichita, Kansas

  • Meridian Clinical Research

    Baton Rouge, Louisiana

  • Benchmark Research - Metairie

    Metairie, Louisiana

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.